HOME >> BIOLOGY >> NEWS
Stronger therapy better for AML with normal genetics

COLUMBUS, Ohio New research is helping select which therapies improve the chances of remission in the largest category of people affected by acute myeloid leukemia (AML) those whose cancer cells have normal-looking chromosomes.

The findings suggest that people receiving more intense therapies are more likely to enter remission and to remain there longer than those receiving lower-dose therapies.

The study was published online Nov. 8 by the Journal of Clinical Oncology.

The Cancer and Leukemia Group B (CALGB) study was initiated by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSU CCC-James). It is part of a larger CALGB cytogenetic trial chaired by Clara D. Bloomfield, professor of internal medicine and the William G. Pace III Professor in Cancer Research, OSU Cancer Scholar and senior adviser to the OSU cancer program.

Unexpectedly, the current study also found that patients who had an enlarged spleen at the time of their initial treatment were less likely to enter remission. AML patients are in remission when leukemic cells are not microscopically detectable among their bone-marrow cells.

"These preliminary findings raise the question of whether additional treatment directed specifically to the spleen might improve remission rates," says first author Sherif S. Farag, assistant professor of internal medicine and a medical oncologist with the OSU CCC-James. "At this point, this is just a hypothesis that needs to be tested, but it may be that the spleen is a sanctuary site for leukemic cells and needs separate treatment."

A diagnosis of AML routinely includes studying patients' leukemic cells for chromosome damage, a process known as cytogenetic analysis. The information helps determine the best therapy and a patient's chance of remission and cure. But 40 percent of AML patients have leukemic cells wit
'"/>

Contact: Darrell E. Ward
Ward-15@medctr.osu.edu
614-293-3737
Ohio State University
29-Nov-2004


Page: 1 2 3

Related biology news :

1. Stronger evidence found linking Epstein-Barr virus and risk of multiple sclerosis
2. Testosterone replacement therapy: How safe for aging men?
3. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
4. Aggressive therapy best for certain AML patients
5. Under magnetic force, nanoparticles may deliver gene therapy
6. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Stem cell therapy rescues motor neurons in ALS model
8. Study identifies new gene therapy tools for inherited blindness
9. Breast cancer and hormone therapy -- A looking-glass mirror?
10. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
11. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
Breaking Biology News(10 mins):
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... the healthcare and technology sector at their fourth annual Conference where founders, investors, ... inspiring speakers and the ELEVATE pitch competition showcasing early stage digital health and ...
(Date:10/5/2017)... ... October 05, 2017 , ... LabRoots , the leading ... around the world, is giving back to cancer research with a month-long promotion supporting ... Now through October 31, shoppers can use promo code PinkRibbon to get 10 percent ...
(Date:10/5/2017)... , ... October 05, 2017 , ... ... develop new applications of its Nanobind DNA/RNA extraction technology . Nanobind is ... silica on the surface and that can be used for a wide variety ...
Breaking Biology Technology:
Cached News: